Open Beta
TREN
MetriLume
TREN

US marketsSPRO

SEC-sourced researchBeta

SPRO

Spero Therapeutics, Inc.

Company comparison ↗

Data passport

CIK
0001701108
Exchange
Nasdaq
Business activity
— · SIC 2834
Financial inputs
6/6
Filing date
Sep 10, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 371,000.0000 USD; December 2025: 12,586,000.0000 USD12.6M USD0 USD0December 2024December 2025
SPRO · Exact amounts and source periods · USD
Period endRevenueFiling date
December 2024371,000.0000Mar 26, 2026
December 202512,586,000.0000Mar 26, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 202512,586,000.00008,572,000.0000-12,624,000.000068,919,000.00009,898,000.0000Mar 26, 2026
December 2024371,000.0000-68,566,000.0000-23,444,000.0000110,543,000.000064,420,000.0000Mar 26, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$12.59MDecember 2025Mar 26, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$371KDecember 2024Mar 26, 202610-K
Net incomeProfitLoss$8.57MDecember 2025Mar 26, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$12.62MDecember 2025Mar 26, 202610-K
Total assetsAssets$68.92MDecember 2025Mar 26, 202610-K
Total liabilitiesLiabilities$9.9MDecember 2025Mar 26, 202610-K

New filings

Explore methodology ↗